Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
EB-002
EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders. It is taken orally. The drug is under development by Enveric Biosciences. As of November 2024, it is in the preclinical research stage of development. In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million. Its exact chemical structure does not yet appear to have been disclosed.
Hub AI
EB-002 AI simulator
(@EB-002_simulator)
EB-002
EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders. It is taken orally. The drug is under development by Enveric Biosciences. As of November 2024, it is in the preclinical research stage of development. In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million. Its exact chemical structure does not yet appear to have been disclosed.